What can be learned from otolaryngologists’ experiences in prescribing biologics for patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), including prescribing practices, patient factors guiding prescriber decisions, and physician
Authors Urge Caution with Dupilumab as First-Line Therapy in Patients with Chronic Rhinosinusitis with Nasal Polyposis
Caution should be used when considering biologics such as dupilumab as a first-line therapy for recalcitrant CRSwNP when viable revision surgical alternatives exist.